Daily Sepsis Research Analysis
Analyzed 28 papers and selected 3 impactful papers.
Summary
Three impactful studies span surveillance, therapeutics, and AI in sepsis: a national time-series from South Africa shows a rapid shift toward Candida auris bloodstream infections during COVID-19; a preclinical NIR-triggered Prussian blue/Fer-1 nanozyme synergistically treats sepsis-associated acute lung injury and reveals a CXCL2/ARF6/NCF1 axis; and a new offline reinforcement learning method (DDRL) outperforms standard CQL while aligning with physician policies for sepsis care.
Research Themes
- Accelerated rise of Candida auris bloodstream infections during COVID-19 waves
- Nanomedicine targeting ferroptosis and oxidative stress in sepsis-associated acute lung injury
- Offline reinforcement learning aligning with clinician policies for sepsis treatment
Selected Articles
1. NIR-responsive prussian Blue/Fer-1 co-loaded nanozymes for synergistic therapy of acute lung injury.
A NIR-triggered Prussian blue/Fer-1 co-loaded nanozyme (Fer-1@PB) delivered synergistic ROS scavenging and ferroptosis inhibition, improving survival and lung function in sepsis-related ALI models. Transcriptomics and validation implicated a CXCL2/ARF6/NCF1 signaling axis.
Impact: Introduces a mechanistically rational, dual-action nanotherapy with demonstrated efficacy in sepsis-associated ALI and identifies a new signaling axis, suggesting a translational pathway for precision interventions.
Clinical Implications: While preclinical, the platform supports a combined anti-oxidative and anti-ferroptotic strategy for sepsis-associated ALI. Translation will require safety, biodistribution, dosing, and NIR delivery feasibility studies.
Key Findings
- Co-loading Ferrostatin-1 with Prussian blue nanozymes created NIR-responsive Fer-1@PB enabling ROS scavenging and ferroptosis inhibition.
- Fer-1@PB improved survival, reduced pulmonary edema and histopathological injury, and restored lung function in cellular and animal sepsis-related ALI models.
- RNA-seq and experimental validation implicated modulation of the CXCL2/ARF6/NCF1 signaling axis as a mechanistic basis for efficacy.
Methodological Strengths
- Integrated in vitro and in vivo validation with functional outcomes and histopathology.
- Mechanistic elucidation via transcriptomics with experimental confirmation.
Limitations
- Preclinical animal and cell models without human clinical data.
- Incomplete characterization of long-term safety, biodistribution, immunogenicity, and clinical feasibility of NIR delivery.
Future Directions: Advance toward IND-enabling studies: GLP toxicology, pharmacokinetics, lung-targeted delivery, NIR penetration optimization, and exploration of combination with standard sepsis care.
Sepsis-associated acute lung injury (ALI) is a critical clinical problem owing to the complex interactions between inflammation and oxidative stress. It is often associated with high mortality rates and a lack of therapeutic options. To simultaneously combat the interconnected inflammatory and oxidative stress pathways in sepsis-associated ALI, we designed near-infrared (NIR)-responsive nanomedicine by co-loading ferroptosis inhibitor Ferrostatin-1 (Fer-1) with Prussian blue nanozymes (denoted as Fer-1@PB) to achieve synergistic therapy and enhanced efficacy. Fer-1@PB combines the multi-enzyme mimetic properties of PB nanoparticle-based nanozyme (PBzyme) for reactive oxygen species (ROS) scavenging and the ferroptosis-inhibitory function of Fer-1 with spatiotemporally controlled burst release under NIR irradiation. The 0.05), and the conclusion of colloidal stability remains completely unchanged. All the above revisions are limited to typographical adjustments, wording accuracy, and minor typo corrections. No experimental data, results, figures, or cistance. Sincerely, Xiaoran Liu (on behalf of all authors) Corresponding author"?> Fer-1@PB nanozymes exhibited strong therapeutic efficacy in cellular and animal sepsis-related ALI models, with an increased survival rate, reduced pulmonary edema and histopathological damage, and recovery of lung function. Mechanistic investigations using transcriptomic analysis (RNA-seq) and experimental validation revealed that the therapeutic effects were mediated by the modulation of the CXCL2/ARF6/NCF1 signaling axis. This study introduces Fer-1@PB as a highly efficient and biosafe nanotherapeutic approach for ALI via synergistic anti-oxidative and anti-inflammatory effects. It also outlines a new molecular mechanism of action, yielding new insights into the precise nanomedicine for inflammatory lung disease.
2. Accelerated Increase in Candida auris Bloodstream Infections during COVID-19 Pandemic, South Africa.
Using national laboratory data (2019–2022), an interrupted time-series showed Candida BSIs increased after COVID-19 onset by 11 cases/week, driven by C. auris (+5/week); C. auris proportion rose from 17% to 31%. Peaks coincided with COVID-19 waves, underscoring urgent surveillance and IPC needs.
Impact: Quantifies a rapid national shift toward C. auris candidemia linked temporally to COVID-19 waves, informing policy for surveillance, diagnostics, and infection prevention.
Clinical Implications: Hospitals should implement enhanced C. auris screening, species-level ID, antifungal stewardship, and targeted IPC, particularly during respiratory virus surges.
Key Findings
- Identified 15,393 candidemia cases (2019–2022), with C. auris comprising 26% overall.
- C. auris proportion increased from 17% (2019) to 31% (2021) (p<0.01).
- Post-pandemic onset, Candida BSIs rose by 11/week (p=0.03), driven by C. auris (+5/week; p<0.01), with peaks coinciding with COVID-19 waves.
Methodological Strengths
- National, multi-sector laboratory coverage with large sample size.
- Interrupted time-series with segmented regression to assess temporal changes.
Limitations
- Ecological, retrospective design limits causal inference and patient-level risk factor assessment.
- Potential confounding by changes in testing practices or healthcare utilization during the pandemic.
Future Directions: Link facility-level trends to patient-level data to identify modifiable risks; evaluate targeted IPC bundles and antifungal stewardship impacts on C. auris transmission.
The COVID-19 pandemic coincided with rising secondary bloodstream infections (BSIs) from multidrug-resistant organisms, including Candida auris. To assess candidemia trends, we conducted a retrospective analysis of blood culture isolates from public and private laboratories in South Africa taken during January 2019-June 2022. We evaluated weekly aggregated Candida BSI counts and COVID-19 cases using segmented regression within an interrupted time-series framework. In total, 15,393 candidemia cases were identified, 70% from the private sector. C. parapsilosis accounted for 39% of cases, whereas C. auris represented 26%. The proportion of C. auris increased significantly from 17% in 2019 to 31% in 2021 (p<0.01). After the pandemic onset, Candida BSIs rose by 11 cases per week (p = 0.03), largely driven by C. auris (+5 cases/week; p<0.01); peaks coincided with COVID-19 waves. Those results highlight an accelerated shift toward C. auris in Candida BSIs and the urgent need for enhanced surveillance, diagnostics, and infection prevention.
3. DDRL:Dyna-Based Discriminative Reinforcement Learning for Optimizing Sepsis Treatment Pathways in Offline Environments.
DDRL combines EMR-driven learning with simulated episodes and a discriminator to suppress out-of-distribution Q-value inflation, aligning with clinician policies while outperforming CQL in expected return across two hospitals.
Impact: Addresses core limitations of offline RL for sepsis by curbing OOD overestimation and improving alignment with physician policy, a key step toward safe clinical decision support.
Clinical Implications: If prospectively validated, DDRL could inform bedside decision support for individualized sepsis therapy while maintaining clinician-aligned actions, potentially improving care consistency.
Key Findings
- Introduced Dyna-Based Discriminative RL leveraging EMR data and simulated episodes to mitigate limited exploration in offline settings.
- Discriminator suppresses Q-values for out-of-distribution actions, reducing deviation from physician policies.
- Across two hospitals, DDRL improved expected return by 3.4% and 5.6% over CQL and exceeded physician policy performance by 18.7% and 8.3%; policy cosine similarity reached 81.68% and 90.90%.
Methodological Strengths
- Multi-center evaluation with quantitative benchmarking against CQL and clinician policies.
- Principled mitigation of out-of-distribution overestimation using a discriminator within a Dyna framework.
Limitations
- Offline evaluation without prospective or interventional validation; improvements in expected return may not translate to clinical outcomes.
- Lack of detailed reporting on cohort sizes, case-mix, and generalizability beyond two centers.
Future Directions: Prospective silent deployment with off-policy evaluation safeguards, domain shift assessment, and eventual randomized clinical evaluation for safety and efficacy.
Optimizing automated sepsis treatment policies using Reinforcement Learning (RL) has gained attention for improving quality of medical care and address physician shortages. However, in an offline setting, an RL agent cannot explore all possible treatment episodes, leading to an overestimation of Q-values for unexplored treatments. This causes a significant deviation from the physician's policy and results in the RL policy converging to a suboptimal policy. To address this problem, we propose Dyna-Based Discriminative Reinforcement Learning (DDRL), which aims to learn an optimal treatment policy that aligns with physician treatment policy. Our method utilizes both Electronic Medical Record (EMR) data and simulated treatment episodes to mitigate the limitations of restricted treatment exploration. Additionally, by leveraging a Discriminator, we suppress the Q-values of out-of-distribution treatments, preventing overestimation and reducing deviation from the physician treatment policies. The method was evaluated using data from Ajou University Hospital and Asan Medical Center. The expected return of the DDRL policy was 7.29 for Asan Medical Center and 4.55 for Ajou University Hospital, outperforming the Conservative Q-Learning (CQL) method by 3.4% and 5.6%, and surpassing the physician's policy by 18.7% and 8.3% respectively. The cosine similarity between DDRL and physician policies was 81.68% for Asan Medical Center and 90.90% for Ajou University Hospital, which is 0.73% and 26.11% higher, respectively, than the CQL method.